Skip to content
Peptidepedia

Tesamorelin Side Effects: Safety Profile, Risks & What to Expect (2026)

From Peptidepedia, the trusted peptide wiki.

Side Effects

Tesamorelin demonstrates generally good tolerability, with most adverse effects ranging from mild to moderate severity.

Common Side Effects (occurring in >5% of patients):

  • Injection site reactions including erythema, pruritus, pain, and swelling, affects approximately 8-13% of users, typically diminishing with continued use and proper injection site rotation
  • Arthralgia (joint pain) and myalgia (muscle pain), occurs in approximately 10-13% of patients, likely related to GH-mediated fluid retention and tissue effects
  • Peripheral edema and paresthesias (tingling sensations), affects roughly 5-6% of users

Less Common Side Effects:

  • Carpal tunnel syndrome symptoms
  • Glucose intolerance
  • Hypersensitivity reactions
Patients with pre-existing glucose intolerance should monitor blood sugar carefully, as GH can antagonize insulin action.

Contraindications:

Tesamorelin remains contraindicated in patients with:

  • Active malignancy
  • Disruption of the hypothalamic-pituitary axis due to conditions such as hypophysectomy or pituitary tumor
  • Pregnancy
  • Known hypersensitivity to tesamorelin or mannitol

Frequently Asked Questions

Tesamorelin stimulates natural GH production rather than introducing exogenous hormone, which maintains physiological pulsatile release patterns and feedback mechanisms. While direct comparison studies remain limited, tesamorelin may offer advantages in terms of reduced pituitary suppression risk, though HGH provides more precise dosing control.

Clinical trials have evaluated tesamorelin use for up to 52 weeks with maintained efficacy and acceptable safety profiles. However, long-term data beyond this period remains limited, and discontinuation typically results in gradual return of visceral fat accumulation.

Tesamorelin remains contraindicated in patients with active malignancy due to theoretical concerns that elevated GH/IGF-1 could promote tumor growth. However, clinical trials have not demonstrated increased cancer incidence with tesamorelin use in appropriate patient populations.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370.
  2. Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat. Journal of Clinical Endocrinology & Metabolism. 2010;95(9):4291-4304.
  3. Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA. 2014;312(4):380-389.
  4. Makimura H, et al. Effects of tesamorelin on cardiometabolic risk factors in HIV-infected patients. Journal of Clinical Endocrinology & Metabolism. 2011;96(9):2831-2838.
  5. Fourman LT, et al. Tesamorelin treatment for liver fat and histology in HIV-associated NAFLD. Journal of Clinical Investigation. 2019;129(11):4608-4615.
  6. Baker LD, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Archives of Neurology. 2012;69(11):1420-1429.
  7. Sevigny JJ, et al. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. 2008;71(21):1702-1708.
  8. Dhillon S. Tesamorelin: A Review of its Use in the Management of HIV-Associated Lipodystrophy. Drugs. 2011;71(8):1071-1091.
  9. FDA Prescribing Information for Egrifta SV (tesamorelin).
  10. World Anti-Doping Agency 2024 Prohibited List.
  11. Spooner LM, et al. Tesamorelin: A Growth Hormone-Releasing Factor Analogue for HIV-Associated Lipodystrophy. Annals of Pharmacotherapy. 2012;46(2):240-247.
  12. Stanley TL, et al. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat. AIDS. 2011;25(10):1281-1288.
←Read the full Tesamorelin guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”